Purple Book reference family · 351(a) biologic
fibrinolysin and desoxyribonuclease combined [bovine], with chloramphenicol (Elase-chloromycetin)
fibrinolysin and desoxyribonuclease combined [bovine], with chloramphenicol is an FDA-licensed reference biologic from Parke-Davis, a Division of Pfizer Inc..
351(a) biologicBLA 050294 Parke-Davis, a Division of Pfizer Inc.
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
1964
Reference product
Originator biologic
351(a)BLA 050294
Elase-chloromycetin fibrinolysin and desoxyribonuclease combined [bovine], with chloramphenicol
Parke-Davis, a Division of Pfizer Inc.
View full reference-product record- Approved
- Marketing
- Disc
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Protection horizon
Reference approval
Approval date of the reference fibrinolysin and desoxyribonuclease combined [bovine], with chloramphenicol product.
63 yr 3 mo ago
fibrinolysin and desoxyribonuclease combined [bovine], with chloramphenicol: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for fibrinolysin and desoxyribonuclease combined [bovine], with chloramphenicol.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
